Pieris Pharmaceuticals - PIRS Operating Margin

Public company logo of Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals (PIRS) is developing respiratory and oncology drugs through strategic alliances utilizing Anticalin proteins. Marginal income from core operations illustrates market dynamics, where 0.00 serves as the final level mark. The company's capital relies on royalties and upfront payments from global partners, although strict staffing cuts and the freezing of tests have created a defensive barrier amid high infrastructure costs.

Pieris Pharmaceuticals Inc (PIRS): Profitability of Operations from 07/04/2022 to 11/19/2026

Pieris Pharmaceuticals (PIRS) - metric breakdowns and financial figures

- price and consensus price forecast:
Fundamental company valuation:Pieris Pharmaceuticals Inc, PIRS
Core merchandise of Pieris Pharma

Pieris Pharmaceuticals (PIRS) cost optimization through R&D outsourcing directly impacts core operational efficiency, as clearly reflected in the average operating margin. This indicator measures the share of profit from the core business before financial and tax obligations, allowing investors to strip away accounting distortions and determine the asset's real profitability before any potential industry contraction.

Main competitors

Operating Profitability haleon.com|Operating Profitability KVUE|Operating Profitability Verona Pharma (VRNA)|Jyong Biotech (MENS) - Operating Profitability Margin|Operating Margin LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Operating Profitability|PRGO - Operating Profitability|Alvotech Corp (ALVO) - Operating Sales Margin|LQDA: Operating Margin|Operating Return on Sales glpg.com (GLPG)|Operating Profitability ANI Pharmaceuticals Inc|MNKD: Operating Profit Rate|Operating Sales Margin AMPH (Amphastar)|PCRX - Operating Return on Sales|Operating Margin SPRY (ars-pharma.com)|Operating Profit Rate TBPH|Aquestive Therapeutics, Inc. - Operating Margin|scpharmaceuticals.com - Operating Profit Ratio|Tectonic (TECX) - Operating Profitability|Operating Sales Margin Tonix Pharmaceuticals Inc.|Operating Profitability sxtchina.com|Operating Sales Margin Eupraxia Pharmaceuticals (EPRX)|Operating Margin BHST|EXOZ - Operating Return on Sales|Oramed - Operating Sales Margin|Entera Bio Ltd. (ENTX) - Operating Return on Sales|HYFT - Operating Profitability|ABVC: Operating Profitability|CPIX: Operating Margin|Quantum BioPharma Ltd. - Operating Profit Rate|FGEN (FibroGen Corp) - Operating Margin|Telomir Pharma (TELO) - Profitability of Operations|Operating Profitability Rani Therapeutics Inc (RANI)|SNYR (Synergy CHC Corp.) - Operating Profit Rate|Operating Profitability Rallybio Corporation RLYB|LEXX: Return on Sales by Operating Profit|PULM - Operating Profitability|Operating Profit Rate PTHL (Pheton Holdings)|Aptorum (APM) - Operating Profitability|LYRA (Lyra Therapeutics) - Operating Profitability|Operating Profitability Impact BioMedical Inc|TNF Pharmaceuticals - Operating Profit Margin|Operating Margin YCBD|Operating Margin PainReform Ltd. (PRFX)|Operating Profitability Altamira Therapeutics Ltd CYTO|LIPO (lipella.com) - Operating Profit Margin|OptiNose - Operating Margin|Procaps (PROC) - Operating Sales Margin|PTPI: Operating Margin|Qilian International (QLI) - Operating Margin|Operating Profitability Acelyrin, Inc.|Operating Margin TFF Pharmaceuticals, Inc.